Skip to main content
. Author manuscript; available in PMC: 2015 Sep 1.
Published in final edited form as: Int J Cancer. 2014 Feb 18;135(5):1238–1246. doi: 10.1002/ijc.28747

Figure 6.

Figure 6

vvDD combination therapy with suntininb (Sutent). (A) Mice (BALB/c) bearing 4T1 (either small tumors (50-100mm3; left panel) or large tumors (300-400mm3; right panel)) were treated with 1×108 PFU vvDD or sunitinib, or the combination of both, with sunitinib therapy beginning 7 days after vvDD treatment. Subsequent tumor growth was followed by caliper measurements (n=8 per group)(combination group performs statistical better than all other treatment groups (p<0.05) from day 21 (4T1 small); or day 12 (4T1 large); (B) Vascular collapse in Renca tumor model. Mice (BALB/c bearing subcutaneous Renca tumors and treated intravenously with 1×108 PFU of vvDD) were imaged for tumor perfusion levels by contrast enhanced ultrasound before and 48h after viral treatment (p=0.08). (C) Anti-tumor effects of vvDD used in combination with sunitinib in Renca tumors. Mice (BALB/c) bearing Renca tumors (50-100mm3) were treated with 1×108 PFU vvDD or sunitinib, or the combination of both, with sunitinib therapy beginning 7 days after vvDD treatment or 7 days before vvDD treatment. Subsequent tumor growth was followed by caliper measurements (n=8 per group)(combination group (vvDD then sunitinib) performs statistical better than all other treatment groups (p<0.05) from day 15).